Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06078735 · ClinicalTrials.gov registry record · NA
Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study
A NA study of Atrial Fibrillation and Hemostasis, sponsored by Kansas City Heart Rhythm Research Foundation.
- Recruiting
- Registry status
- NA
- Development phase
- 110
- Enrollment target
- 6
- Study locations
NCT06078735: Recruiting NA study of Atrial Fibrillation and Hemostasis, sponsored by Kansas City Heart Rhythm Research Foundation.
NCT06078735 is a NA study of Atrial Fibrillation and Hemostasis that is actively recruiting participants, run by Kansas City Heart Rhythm Research Foundation. The registered enrollment target is 110 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06078735, a NA study of Atrial Fibrillation and Hemostasis, is actively recruiting participants, sponsored by Kansas City Heart Rhythm Research Foundation.
- RECRUITING
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
- 6
- Study locations
Study Summary
The LockeT II study is a single center, prospective randomized study. It is intended to study the effectiveness of using LockeT device to gain hemostasis after venous procedures as compared to Manual Compression (MC). Approximately 110 patients will be enrolled.
Primary Outcome
Effectiveness of using the LockeT suture retention device to gain hemostasis after venous procedures as compared to standard Manual Compression (MC) will be assessed.
Conditions Studied
Interventions
- DEVICE Vascular closure with LockeT device
Study Locations (6)
Missouri
- Centerpoint Medical Center Clinic - Independence
- Centerpoint Medical Center - Independence
- Research Medical Center Clinic - Kansas City
- Research Medical Center - Kansas City
Kansas
- Kansas City Heart Rhythm Institute - Roe Clinic - Overland Park
- Overland Park Regional Medical Center - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2024-12 |
| Phase | NA |
What NCT06078735 shows while recruiting
NCT06078735 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Vascular closure with LockeT device is the first listed.
NCT06078735 lists 6 locations in 2 states (Missouri, Kansas).
Frequently Asked Questions
What is clinical trial NCT06078735 about?
NCT06078735 is a clinical study titled "Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study". The LockeT II study is a single center, prospective randomized study. It is intended to study the effectiveness of using LockeT device to gain hemostasis after venous procedures as compared to Manual Compression (MC). Approximately 110 patients will be enrolled.
What is the current status of trial NCT06078735?
This trial is currently recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2023-10-02. Estimated completion is 2024-12.
What conditions does trial NCT06078735 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Hemostasis.
What interventions are being tested in trial NCT06078735?
The interventions under investigation include: Vascular closure with LockeT device (DEVICE).
Who is sponsoring clinical trial NCT06078735?
This trial is sponsored by Kansas City Heart Rhythm Research Foundation, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06078735 being conducted?
This trial has 6 study locations across Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06078735's enrollment target sits among peer trials
110 137th of 202 higher than 66 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
-
The CONFORM Pivotal Trial
RECRUITING · NA
-
The Fourth Left Atrial Appendage Occlusion Study
RECRUITING · NA
-
Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI